15th International Conference on Malignancies in AIDS and Other Acquired Immunideficiencies

154 Pages·2015·4.57 MB·English

15th International Conference on
Malignancies in AIDS and
Other Acquired Immunodeficiencies
October 26-27, 2015
Lister Hill Auditorium
NIH Main Campus
Bethesda, Maryland
Office of HIV and AIDS Malignancy | National Cancer Institute

National Institutes of Health | U.S. Department of Health and Human Services
Acknowledgments

Program Committee for Scientific Input
and
National Institute of Dental and Craniofacial
Research for Financial Support
PROGRAM

October 26
Day 1 Poster Setup
Highlighted Poster Setup (will stay up for the entire meeting)
Day 1 Abstracts 1-14 and 15-58

October 27
8:00 a.m. - 8:15 a.m. Poster Viewing
Day 2 Abstracts 1-14 and 59-98

October 26

8:00 a.m. - 8:30 a.m. Day 1 Poster Setup
Highlighted Poster Setup (will stay up for the entire meeting)

8:30 a.m. - 8:45 a.m. Welcome
Robert Yarchoan, M.D.
Director
Office of HIV and AIDS Malignancy
National Cancer Institute, NIH

8:45 a.m. - 9:00 a.m. Opening Remarks
Douglas R. Lowy, M.D., FRACP
NCI Acting Director
National Cancer Institute, NIH

9:00 a.m. - 10:30 a.m. Session 1: HPV-Associated Diseases and HIV
Moderator: Joel Palefsky, M.D., FRCP(C)
University of California, San Francisco

9:00 a.m. - 9:30 a.m. P1. Incorporating HPV Testing in Cervical Cancer Screening for HIV+
Women
Howard Strickler, M.D., M.P.H.
Albert Einstein College of Medicine

9:30 a.m. - 10:00 a.m. P2. CpG Methylation of HPV16 and Other Oncogenic Human
Papillomaviruses (HPVs) Is Associated With High-Grade Cervical
Intraepithelial Neoplasia (CIN)
Robert D. Burk, M.D.
Albert Einstein College of Medicine

10:00 a.m. - 10:30 a.m. P3. Synthetic DNA Vaccines for Difficult Immune Targets Including HPV
Matthew P. Morrow, Ph.D.
Inovio Pharmaceuticals

10:30 a.m. - 11:00 a.m. Break and Poster Viewing

- 1 -
11:00 a.m. - 12:15 p.m. Session 2: EBV and Lymphomagenesis
Moderator: Richard F. Ambinder, M.D., Ph.D.
Johns Hopkins University School of Medicine

11:00 a.m. - 11:30 a.m. P4. Epstein-Barr Virus Oncoprotein Super-Enhancers Control B Cell
Growth
Elliott D. Kieff, M.D., Ph.D.
Harvard Medical School

11:30 a.m. - 11:45 a.m. O1. EBV-Mediated B-cell Transformation Is Suppressed by Oncogene-
Induced Senescence Due to Depletion of Nucleotide Pools
Micah A. Luftig, Ph.D.
Duke University

11:45 a.m. - 12 noon O2. Increased Levels of Bregs Are Seen Prior to AIDS Non-Hodgkin
Lymphoma Diagnosis
Marta Epeldegui, Ph.D.
University of California, Los Angeles

12 noon - 12:15 p.m. O3. Exquisite Sensitivity of KSHV-Associated Lymphomas to a New
Nucleoside Analog Activated by Overexpressed Adenosine Kinase
Jouliana Sadek, Ph.D.
Weill Cornell Medical College

12:15 p.m. - 1:00 p.m. Lunch

1:00 p.m. - 2:00 p.m. Poster Viewing (presenters to stand by their posters)

2:00 p.m. - 3:00 p.m. Session 3: Immune Response to Viral Infections
Moderator: Otoniel Martinez-Maza, Ph.D.
University of California, Los Angeles

2:00 p.m. - 2:30 p.m. P5. The Innate Immune Response to KSHV
Blossom Damania, Ph.D.
The University of North Carolina at Chapel Hill

2:30 p.m. - 3:00 p.m. P6. IFNL4 and HCV Infection
Thomas O’Brien, M.D., M.P.H.
National Cancer Institute, NIH

3:00 p.m. - 3:30 p.m. Break and Poster Viewing

3:30 p.m. - 5:15 p.m. Session 4: Epidemiology
Moderator: Corey Casper, M.D., M.P.H.
University of Washington and
Fred Hutchinson Cancer Research Center

3:30 p.m. - 4:00 p.m. P7. Cancer in HIV-Infected People and Solid Organ Transplant Recipients:
Lessons Learned and Open Questions
Eric A. Engels, M.D., M.P.H.
National Cancer Institute, NIH

- 2 -
4:00 p.m. - 4:15 p.m. O4. Risk of Both AIDS-Related and Non-AIDS-Related Cancers Decreased
by Early Initiation of Antiretroviral Therapy: Results From the START Trial
(INSIGHT 001)
Karen L. Klingman, M.D.
National Institute of Allergy and Infectious Diseases, NIH

4:15 p.m. - 4:30 p.m. O5. Long-Term Viral Suppression Predicts Lower Cancer Incidence Among
HIV-Infected Veterans, but Higher Than Among Uninfected
Lesley S. Park, Ph.D., M.P.H.
Stanford University School of Medicine

4:30 p.m. - 4:45 p.m. O6. Risk of Kaposi Sarcoma in HIV-Positive Adults on ART: A Global
Analysis
Julia Bohlius, M.D., M.Sc.P.H.
University of Bern

4:45 p.m. - 5:00 p.m. O7. Determinants of Shedding of Kaposi Sarcoma-Associated Herpesvirus
in Saliva Among Ugandan Mothers and Children
Vickie Marshall, M.S.
Leidos Biomedical Research, Inc.
Frederick National Laboratory for Cancer Research

5:00 p.m. - 5:15 p.m. O8. Kaposi Sarcoma in HIV-Infected Children and Adolescents in Central
Malawi: A Novel Clinical Staging Classification Determines Risk
Stratification
Nader Kim El-Mallawany, M.D.
New York Medical College

5:15 p.m. End of Day 1

- 3 -
October 27

8:00 a.m. - 8:15 a.m. Day 2 Poster Setup and Viewing

8:15 a.m. - 8:25 a.m. Opening Comments

8:25 a.m. - 10:00 a.m. Session 5: Round Table Discussion of KSHV Transmission: Implications for
Public Health Approaches to Reduce Transmission
Each speaker has 15 minutes.

8:25 a.m. - 8:30 a.m. Session Overview
Robert Yarchoan, M.D.
National Cancer Institute, NIH

8:30 a.m. - 8:45 a.m. T1. KSHV Transmission Globally and Lifestyle Factors That Play a Role in
Acquisition
Jeffrey Martin, M.D., M.P.H.
University of California, San Francisco

8:45 a.m. - 9:00 a.m. T2. KSHV Risk Factors for Early Childhood Infection
Charles Wood, Ph.D.
University of Nebraska, Lincoln

9:00 a.m. - 9:15 a.m. T3. Comparison of Kaposi Sarcoma-Associated Herpesvirus Transmission
With Epstein-Barr Virus and Other Human Herpesviruses in Ugandan
Households
Soren Gantt, M.D., Ph.D.
University of British Columbia

9:15 a.m. - 9:30 a.m. T4. Prevalence and Incidence in the United States in the cART Era
Denise Whitby, Ph.D.
Leidos Biomedical Research, Inc.
Frederick National Laboratory for Cancer Research

9:30 a.m. - 10:00 a.m. Panel Discussion

10:00 a.m. - 10:30 a.m. Break and Poster Viewing

10:30 a.m. - 12 noon Session 6: Kaposi's Sarcoma-Associated Herpesvirus (KSHV)/Human
Herpesvirus 8 (HHV8) Biology
Moderator: Dirk Dittmer, Ph.D.
The University of North Carolina at Chapel Hill

10:30 a.m. - 11:00 a.m. P8. Deregulation of Host Cellular Long Noncoding RNAs by Kaposi
Sarcoma-Associated Herpesvirus
Rolf Renne, Ph.D.
University of Florida

11:00 a.m. - 11:15 a.m. O9. Comprehensive RNAseq Analysis of KSHV Gene Expression in Kaposi
Sarcoma Tumors and Correlation With In Vitro Infection Models
Timothy Rose, Ph.D.
Center for Global Infectious Disease Research

- 4 -
11:15 a.m. - 11:30 a.m. O10. KSHV Induces Revision of B Cell Receptors
Jennifer E. Totonchy, Ph.D.
Weill Cornell Medical College

11:30 a.m. - 11:45 a.m. O11. The cryoEM Structure and Structure-Guided Mutagenesis of KSHV
Capsid
Xinghong Dai, Ph.D.
University of California, Los Angeles

11:45 a.m. - 12 noon O12. Modeling of the KSHV Episome-Host Chromatin Synapse by Super-
Resolution Localization Microscopy
Margaret J. Grant, M.S., B.S.
University of Virginia, Charlottesville

12 noon - 12:45 p.m. Lunch

12:45 p.m. - 1:45 p.m. Poster Viewing (presenters to stand by their posters)

1:45 p.m. - 3:00 p.m. Session 7: Lung Cancer
Moderator: Alexandra M. Levine, M.D., MACP
City of Hope

1:45 p.m. - 2:15 p.m. P9. Screening for Lung Cancer in HIV+ Persons in the Context of General
Lung Cancer Screening Guidelines
Kristina Crothers, M.D.
University of Washington

2:15 p.m. - 2:30 p.m. O13. Benefits and Harms of Lung Cancer Screening in HIV-Infected
Individuals: A Simulation Study
Chung Yin Kong, Ph.D.
Massachusetts General Hospital

2:30 p.m. - 2:45 p.m. O14. Lung Cancer Screening and Smoking Behavior in HIV+ Smokers
Keith M. Sigel, M.D.
Mount Sinai School of Medicine

2:45 p.m. - 3:00 p.m. O15. Characteristics of HIV+ Lung Cancer Patients Undergoing Surgical
Resection at an Urban Center With High HIV Prevalence: Implications for
Lung Cancer Screening
Vipul Pareek, M.D.
Montefiore Medical Center

3:00 p.m. - 3:30 p.m. Break and Poster Viewing

3:30 p.m. - 4:30 p.m. Session 8: HPV Pathogenesis
Moderator: Erle S. Robertson, Ph.D.
University of Pennsylvania

3:30 p.m. - 4:00 p.m. P10. Effect of HIV on Oral HPV Infection and Oropharyngeal Cancer
Gypsyamber D’Souza, Ph.D.
Johns Hopkins Bloomberg School of Public Health

- 5 -
4:00 p.m. - 4:15 p.m. O16. Homologous Prime-Boost With an HPV-E6/E7 Immunotherapy Plus
PD-1 Checkpoint Inhibition Results in Tumor Regression and Reduction in
PD-L1 Expression
Adrian E. Rice, Ph.D.
Etubics Corporation

4:15 p.m. - 4:30 p.m. O17. High-Risk Human Papillomavirus Oncoprotein E6 Induces FoxM1 in
Human Keratinocytes Through Transcriptional Regulation by Grainyhead-
Like 2 (GRHL2)
Mo K. Kang, D.D.S., Ph.D.
University of California, Los Angeles, School of Dentistry

4:30 p.m. - 5:30 p.m. Session 9: Clinical Trials in HIV-Associated Malignancies
Moderator: Richard Little, M.D.
National Cancer Institute, NIH

4:30 p.m. - 4:45 p.m. O18. Lenalidomide and Pomalidomide Inhibit KSHV-Induced
Downregulation of MHC Class I Expression in Primary Effusion Lymphoma
Cells
David A. Davis, Ph.D., M.S.
National Cancer Institute, NIH

4:45 p.m. - 5:00 p.m. O19. Radiation-Sparing Treatment of Acquired Immune Deficiency
Syndrome (AIDS)-Related Primary Central Nervous System Lymphoma
(PCNSL) With Highly Active Antiretroviral Therapy (HAART), Rituximab (R),
and High-Dose Methotrexate With Leucovorin Rescue (HD-MTX)
Thomas S. Uldrick, M.D., M.S.
National Cancer Institute, NIH

5:00 p.m. - 5:15 p.m. O20. AMC-085: A Pilot Trial of AVD and Brentuximab Vedotin in the Upfront
Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma. A Trial of the
AIDS Malignancy Consortium
Paul G. Rubinstein, M.D.
John H. Stroger, Jr. Hospital of Cook County

5:15 p.m. - 5:30 p.m. O21. Non-Myeloablative Haploidentical Allogeneic Bone Marrow
Transplantation in HIV-Infected Individuals
Richard F. Ambinder, M.D., Ph.D.
Johns Hopkins University School of Medicine

5:30 p.m. Meeting Adjourned

- 6 -
PROGRAM COMMITTEE

Program Co-Chairs

Geraldina Dominguez, Ph.D. Robert Yarchoan, M.D.
Program Director Director
Office of HIV and AIDS Malignancy Office of HIV and AIDS Malignancy
National Cancer Institute Chief
National Institutes of Health HIV and AIDS Malignancy Branch
Building 31, Room 33A-33 Center for Cancer Research
31 Center Drive National Cancer Institute
Bethesda, MD 20892-2440 National Institutes of Health
[phone] Building 10, Room 6N-106
[email protected] 10 Center Drive
Bethesda MD 20892-1868
[phone]
[email protected]

Program Committee

Richard F. Ambinder, M.D., Ph.D. Corey Casper, M.D., M.P.H.
Director Head, Global Oncology
Division of Hematologic Malignancies Member
Professor of Oncology Vaccine and Infectious Disease Division
Johns Hopkins University School of Medicine Fred Hutchinson Cancer Research Center
CRB1, Room 389 Professor of Medicine, Epidemiology and Global Health
1650 Orleans Street University of Washington
Baltimore, MD 21287 M1-B140
[phone] 1100 Fairview Avenue, North
[email protected] Seattle, WA 98109
[phone]
Kishor Bhatia, Ph.D., FRCPath [email protected]
Director
AIDS Malignancy Program Ethel Cesarman, M.D., Ph.D.
Office of HIV and AIDS Malignancy Professor
National Cancer Institute Pathology and Laboratory Medicine
National Institutes of Health Weill Cornell Medical College
Building 31, Suite 3A-33 1300 York Avenue
31 Center Drive New York, NY 10065
Bethesda, MD 20892-2440 [phone]
[phone] [email protected]
[email protected]
Dirk Dittmer, Ph.D.
Professor
Department of Microbiology and Immunology
Lineberger Comprehensive Cancer Center
Center for AIDS Research
The University of North Carolina at Chapel Hill
Chapel Hill, NC 27599-7290
[phone]
[email protected]

- 7 -
Gypsyamber D’Souza, Ph.D. Elliott D. Kieff, M.D., Ph.D.
Associate Professor Harriet Ryan Albee Professor of Microbiology and
Department of Epidemiology Molecular Genetics
Johns Hopkins Bloomberg School of Public Health Harvard Medical School
Room E6132B Director of Infectious Diseases
615 North Wolfe Street Brigham and Women’s Hospital
Baltimore, MD 21205 181 Longwood Avenue
[phone] Boston, MA 02115
[email protected] [phone]
[email protected]
Eric A. Engels, M.D., M.P.H
Senior Investigator Alexandra M. Levine, M.D., MACP
Division of Cancer Epidemiology and Genetics Chief Medical Officer
National Cancer Institute Professor of Hematology/HCT
National Institutes of Health City of Hope National Medical Center
Room 6E226 1500 East Duarte Road
9609 Medical Center Drive Duarte, CA 91010
Rockville, MD 20850 [phone]
[phone] [email protected]
[email protected]
Richard Little, M.D.
Thomas Gross, M.D., Ph.D. Head
Deputy Director of Science Hematologic, HIV, and Stem Cell Therapeutics
Center for Global Health Clinical Investigations Branch
National Cancer Institute National Cancer Institute
National Institutes of Health National Institutes of Health
Room 3W534 Room 5W426
9609 Medical Center Drive 9609 Medical Center Drive
Rockville, MD 20850 Rockville, MD 20850
[phone] [phone]
[email protected] [email protected]

Missak Haigentz, M.D. Otoniel Martinez-Maza, Ph.D.
Associate Professor of Clinical Medicine Professor
Albert Einstein College of Medicine David Geffen School of Medicine
Hofheimer Building, Room 100 UCLA AIDS Institute
111 East 210th Street University of California, Los Angeles
Bronx, NY 10467 BSRB 173
[phone] 615 Charles E. Young Drive, South
[email protected] Los Angeles, CA 90095-7363
[phone]
Rebecca Liddell Huppi, Ph.D. [email protected]
Program Director
Office of HIV and AIDS Malignancy Sam Mbulaiteye, M.D.
National Cancer Institute Senior Investigator
National Institutes of Health Division of Cancer Epidemiology and Genetics
Building 31, Room 3A-33 National Cancer Institute
31 Center Drive National Institutes of Health
Bethesda, MD 20892-2440 Room 6E118
[phone] 9609 Medical Center Drive
[email protected] Rockville, MD 20850
[phone]
[email protected]

- 8 -